Johnson & Johnson (JNJ)
NYSE · New Brunswick, New Jersey, USA · Founded 1886 · CEO Joaquin Duato
Valuation summary
$175.25 fair value versus $267.14 in the market, a difference of -34.4%. Rated Sell.
| Fair value per share | $175.25 |
| Current share price | $267.14 |
| Upside / downside | -34.4% |
| Bear case | $109.02 |
| Bull case | $272.62 |
| Discount rate (WACC) | 7.9% |
| Terminal growth | 2.40% |
| Market capitalisation | $643B |
| EV / Sales | 7.0x |
About Johnson & Johnson
Founded in 1886 by three Johnson brothers in New Brunswick, New Jersey, originally making sterile surgical dressings. Joaquin Duato is CEO. After spinning off its consumer health business as Kenvue in 2023, J&J is a focused pharmaceutical and medical technology company. Innovative Medicine covers oncology (Darzalex, Carvykti), immunology (Tremfya, Stelara) and neuroscience. MedTech sells surgical robotics through Ottava, orthopaedics, cardiovascular devices including the Abiomed heart pump, and vision care. It carries a AAA-equivalent credit rating, rarer than a triple-A sovereign.
Investment case
- Balance sheet strength is exceptional, giving it the ability to acquire growth when others cannot afford to.
- Diversification across pharma and devices smooths the patent cliffs that hit pure pharmaceutical companies.
- Over six decades of consecutive dividend increases, a record almost nothing in the market matches.
Key risks
- Stelara has lost exclusivity and biosimilar erosion is a real revenue headwind.
- Talc litigation remains unresolved and the potential liability is difficult to size with confidence.
- Mid single-digit growth means the stock is a yield and stability holding, not a compounder.
Recent developments
- 2026-10-13 · Q3 sales up 5.9% to $25.4bn on MedTech growth; 2026 guidance raised to $101.0bn-$101.4bn of sales and $11.05-$11.15 adjusted EPS source
- 2026-09-25 · Five-year data showed a single Carvykti infusion gave treatment-free remission in 50% of early-line relapsed myeloma patients source
- 2026-09-21 · Caplyta showed significant improvement in bipolar mania in a pivotal Phase 3 study source
Revenue by segment
| Innovative Medicine | 64% |
| MedTech | 36% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $105.3B | $19.6B |
| Year 2 | $113.5B | $20.9B |
| Year 3 | $122.3B | $22.4B |
| Year 4 | $131.9B | $24.0B |
| Year 5 | $142.2B | $25.6B |
What the street says
Treated as the defensive anchor of healthcare portfolios. The recurring question is whether the pipeline can offset Stelara erosion without a large acquisition.
Comparable companies: TMO · ABBV · AZN · ABT · SYK · MRK · NVS · GILD
Open the interactive model, price chart and sensitivity grid →